News for GTHP Stock

Guided Therapeutics Receives $700,000 Purchase Order and Initial Payment from New Chinese Distributor Guided Therapeutics Receives $100,000 from SMI’s Investment Partners to Continue Commercialization Process of LuViva in China Guided Therapeutics Receives Order and Full Payment From Indonesia for 4 LuViva Systems and 1,200 Disposables Guided Therapeutics Announces Filing of Application for NMPA Approval to Market and Sell LuViva in China Guided Therapeutics’ Announces Data from Chinese NMPA Clinical Study Signed Off by All Four Clinical Sites With Better Than Expected Results Leading Cervical Cancer Doctors Support Approval of LuViva in China Based on Preliminary Review of Clinical Trial Results Guided Therapeutics Announces Completion of Clinical Study for Chinese Regulatory Approval Guided Therapeutics Provides Update on Start of Clinical Trial for US FDA Approval Guided Therapeutics Announces New Agreement and Purchase Orders from Shandong Yaohua Medical Instrument Corporation Guided Therapeutics Signs Agreement to Begin Clinical Trial for US FDA Approval Guided Therapeutics Provides Update of Significant Progress in Chinese Clinical Study for Marketing Approval of the LuViva Advanced Cervical Scan Guided Therapeutics Closes $3.3 Million Bridge Financing Guided Therapeutics Receives Institutional Review Board Approval to Start Clinical Study for FDA Approval of the LuViva® Advanced Cervical Scan Guided Therapeutics Announces Testing Completion of First 150 Patients in Chinese Clinical Study and Receives Milestone Payment of $177,740 Guided Therapeutics Announces Start of Chinese Clinical Trial for Approval to Market and Sell LuViva in China Guided Therapeutics Ships LuViva Devices to China for Start of Clinical Trial; Receives Additional $100,000 Payment Guided Therapeutics Receives Notification of Successful Clinical Trial Regulatory Review and $133,000 Payment from China New European Published Study Shows LuViva Detects 20% More Precancerous and Cancerous Cervical Disease than HPV Test Guided Therapeutics Receives News from Chinese State Food and Drug Administration that LuViva Meets Product Technical Requirements Guided Therapeutics Replaces Convertible Note Facility and Significantly Reduces Dilution Guided Therapeutics Closes $2.114 Million Series F Preferred Stock Financing Guided Therapeutics Raises US $1.1 Million in New Preferred Stock Offering Guided Therapeutics Makes Final Payment to GPB Capital Holdings for Secured Notes Guided Therapeutics Receives New Half Million Dollar Purchase Order from China Guided Therapeutics Announces Sales and Training Center in Budapest